Copyright © 2001 by the European Society of Cardiology.
Combination treatment in stable effort angina using trimetazidine and metoprolol. Results of a randomized, double-blind, multicentre study (TRIMPOL II)
a Department of Ischemic Heart Disease, National Institute of Cardiology, Warsaw, Poland
b II Department of Internal Disease, City Hospital, Pozna
, Poland
c I Department of Internal Disease, City Hospital, PCK, Bia
ystok, Poland
d Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
e I Department of Cardiology, Institute of Cardiology, Silesian School of Medicine, Katowice, Poland
f Department of Cardiology, Medical University of Biaystok, Biaystok, Poland
g Voivodship Cardiological Center, om
a, Poland
h Department of Cardiology, Voivodship Hospital, Siedlce, Poland
i Cardiologic Diagnostics and Rehabilitation Center, Wrocaw, Poland
revised July 13, 2001; accepted July 18, 2001
Abstract
Aims To assess the antiischaemic efficacy and tolerability of the metabolic agent trimetazidine in combination with metoprolol in patients with stable effort angina.
Methods This was a randomized, multicentre, double-blind, placebo-controlled parallel group study. A total of 426 male and female patients with stable, effortinduced angina and documented coronary artery disease received either placebo or trimetazidine 20mg three times daily in addition to metoprolol 50mg twice daily. Treadmill exercise tests were performed at weeks (–1), 0, 4 and 12.
Results After 12 weeks, there were significantly greater improvements in the metoprolol + trimetazidine group than in the metoprolol + placebo group in: time to 1mm ST segment depression, total workload, time to onset of angina, maximum ST segment depression, mean weekly number of angina attacks, mean weekly nitrate consumption, and grade of anginal pain. There was no evidence of any development of tolerance to trimetazidine. The tolerability of trimetazidine was excellent.
Conclusions Therapy with trimetazidine plus metoprolol produced significant improvements in exercise stress tests and the symptoms of angina relative to metoprolol alone. With its metabolic effect, devoid of any haemodynamic action, trimetazidine is useful for combination therapy in patients with stable angina insufficiently controlled by monotherapy with a beta-blocker.
Key Words: Stable angina, trimetazidine, metoprolol, combination therapy, metabolic agent, exercise testing
f1 Correspondence: Professor Hanna Szwed, National Institute of Cardiology, Ischemic Heart Disease Department, 1 Sparta
ska Street, 02-637 Warsaw, Poland.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Zerumsky and B. F. McBride Ranolazine in the management of chronic stable angina Am. J. Health Syst. Pharm., December 1, 2006; 63(23): 2331 - 2338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Steg and D. Tchetche Pharmacologic management of stable angina: role of ivabradine Eur. Heart J. Suppl., September 1, 2006; 8(suppl_D): D16 - D23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Parang, B. Singh, and R. Arora Metabolic Modulators for Chronic Cardiac Ischemia Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4): 217 - 223. [Abstract] [PDF]
|
|
|
|
|
|
P. Gabriel Steg and D. Himbert Unmet medical needs and therapeutic opportunities in stable angina Eur. Heart J. Suppl., September 1, 2005; 7(suppl_H): H7 - H15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lee, J. Horowitz, and M. Frenneaux Metabolic manipulation in ischaemic heart disease, a novel approach to treatment Eur. Heart J., April 2, 2004; 25(8): 634 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Thadani Current Medical Management of Chronic Stable Angina Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S11 - S29. [Abstract] [PDF]
|
|
|
|
 |
|
 G. D. Lopaschuk, R. Barr, P. D. Thomas, and J. R.B. Dyck Beneficial Effects of Trimetazidine in Ex Vivo Working Ischemic Hearts Are Due to a Stimulation of Glucose Oxidation Secondary to Inhibition of Long-Chain 3-Ketoacyl Coenzyme A Thiolase Circ. Res., August 8, 2003; 93 (3): e33 - e37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Lopaschuk and M. Marzilli Mode of Action of Trimetazidine and Other New Metabolic Agents in the Treatment of Ischemic Heart Disease Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 91 - 96. [PDF]
|
|
|
|
|
|
M. Frenneaux New tricks for an old drug Eur. Heart J., December 2, 2002; 23(24): 1898 - 1899. [PDF]
|
|
|
|
 |
|
 R. Liao, M. Jain, L. Cui, J. D'Agostino, F. Aiello, I. Luptak, S. Ngoy, R. M. Mortensen, and R. Tian Cardiac-Specific Overexpression of GLUT1 Prevents the Development of Heart Failure Attributable to Pressure Overload in Mice Circulation, October 15, 2002; 106(16): 2125 - 2131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Meurin Does 'more' mean maximal therapy Eur. Heart J., September 2, 2002; 23(18): 1480 - 1480. [Full Text] [PDF]
|
|
|
|
|
|
C. Mannheimer and T. Eliasson A reply Eur. Heart J., September 2, 2002; 23(18): 1480 - 1480. [Full Text] [PDF]
|
|